ATRA
NASDAQ · Biotechnology
Atara Biotherapeutics Inc
$8.09
-0.42 (-4.94%)
Financial Highlights (FY 2026)
Revenue
100.27M
Net Income
27.14M
Gross Margin
82.4%
Profit Margin
27.1%
Rev Growth
+23.9%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.4% | 82.4% | 58.2% | 58.2% |
| Operating Margin | 29.7% | 26.7% | -3.7% | -3.7% |
| Profit Margin | 27.1% | 25.7% | -2.9% | -3.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 100.27M | 80.96M | 4.60M | 4.74M |
| Gross Profit | 82.66M | 66.74M | 2.67M | 2.76M |
| Operating Income | 29.77M | 21.63M | -170,760 | -175,722 |
| Net Income | 27.14M | 19.72M | -132,709 | -155,737 |
| Gross Margin | 82.4% | 82.4% | 58.2% | 58.2% |
| Operating Margin | 29.7% | 26.7% | -3.7% | -3.7% |
| Profit Margin | 27.1% | 25.7% | -2.9% | -3.3% |
| Rev Growth | +23.9% | +23.9% | -8.7% | +11.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.46M | 1.46M | 15.40M | 16.39M |
| Total Equity | 41.25M | 41.25M | 18.11M | 18.20M |
| D/E Ratio | 0.04 | 0.04 | 0.85 | 0.90 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 31.53M | 24.19M | -214,542 | -195,381 |
| Free Cash Flow | — | — | -85,981 | -141,773 |